EXPLORE OUR CLINICAL TRIALS AT ACC.19
To further confirm safety and effectiveness of the Medtronic HeartWare™ HVAD™ system when used as intended for DT in real-world clinical practice.
A post-approval on-label study to further enhance scientific understanding of the implant procedure, optimized blood pressure management, and anticoagulation/ antiplatelet therapy in patients receiving an HVAD for DT. Patients participating in DT PAS are eligible for co-enrollment in Apogee.
Explore clinical trial options for patients with severe mitral regurgitation.
Transcatheter Mitral Valve Replacement
CAUTION: Investigational device. Limited by federal law (USA) to investigational use. Exclusively for clinical investigation.
Committed to advancing DAPT evidence in high-bleeding risk patients with Resolute Onyx™ DES.
Resolute Onyx™ DES
Zotarolimus-eluting Coronary Stent System
Multi-electrode Renal Denervation Catheter
Caution: Investigational device. Limited by federal law (USA) to investigational use in the USA and Japan. Exclusively for clinical investigation.
©2019 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution in the USA only.